Profile: Illumina Inc (ILMN.O)
29 Jul 2016
Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. Its BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has operations in the United States, Europe, Asia-Pacific and other markets.
The Company's sequencing platforms are used to perform whole-genome, de novo and exome sequencing, and targeted resequencing of specific gene regions and genes. The Company's deoxyribonucleic acid (DNA) sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform various assays simultaneously. Illumina's iScan array scanner system and its NextSeq 550 system can be used to image the arrays. Illumina has developed various library preparation and sequencing kits to manage workflows and analysis. Its sequencing applications include whole-genome sequencing kits, which sequence genomes of various sizes, and targeted resequencing kits, which can sequence exomes, specific genes or other genomic regions of interest. The Company also provides whole-genome sequencing, genotyping and NIPT services.
The Company competes with Affymetrix, Inc., Agilent Technologies, Inc., BGI, Pacific Biosciences of California, Inc., QIAGEN N.V., Roche Holding AG. and Thermo Fisher Scientific, Inc.
5200 Illumina Way
SAN DIEGO CA 92122-4616
Company Web Links
- BRIEF-Illumina increases size of board from eight to nine members
- BRIEF-Illumina names Philip Schiller to its board
- BRIEF-Illumina reports Q2 adj. earnings $0.86/shr
- BRIEF-Enzo Biochem says Enzo Life Sciences reached settlement with Illumina that included payment of $21 mln to Enzo
- BRIEF-Natera and Illumina extend supply agreement, broaden existing partnership to include oncology field